glucagon-like peptide 1 receptor agonist(English)
- reduces 3-point major adverse cardiovascular events by 14% in patients with T2D. The benefits of GLP1-RA to reduce ASCVD were at least as large among people with estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m2
- ASCVD, CKD, CVD, GIP, T2DM
- Receptors, Diabetes, Cardiology, Kidney and adrenals
- https://doi.org…jpc.2023.100502
- https://doi.org…000000000001209